Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Completes Tipifarnib Submission For Leukemia Under Pilot 1 Program

This article was originally published in The Pink Sheet Daily

Executive Summary

The oral oncologic, known by the proposed trade name Zarnestra, could be approved by the end of the first half based on J&J's filing under the continuous marketing application pilot program and an expected six-month review. Submission is premised on Phase II response data.

You may also be interested in...



J&J Zarnestra Receives “Not Approvable” Letter From FDA

Oral leukemia agent is not approvable based on Phase II clinical trials, the agency said. J&J maintains it is committed to developing tipifarnib and will determine “appropriate next steps.”

J&J Zarnestra Receives “Not Approvable” Letter From FDA

Oral leukemia agent is not approvable based on Phase II clinical trials, the agency said. J&J maintains it is committed to developing tipifarnib and will determine “appropriate next steps.”

J&J Zarnestra Efficacy Rate Likely To Be Focus Of Oncology Cmte. Review

FDA finds lower rate of complete responses in acute myeloid leukemia patients compared to Johnson & Johnson's analysis. Zarnestra (tipifarnib) oral dosing and low side-effect profile compared to standard chemotherapy may prove positive in the committee's evaluation.

Topics

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel